With a stock price of $4.41, X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) is among the 10 Unrivaled Penny Stocks to Buy Now.
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) reported first-quarter revenue of $2.71 million on May 6, compared with analyst consensus estimates of $3.2 million
Management stated that its top priority remains the execution and enrollment of the pivotal Phase 3 4WARD trial evaluating mavorixafor in chronic neutropenia, with full enrollment expected by the end of the third quarter. The company also highlighted that the European Commission granted marketing authorization for XOLREMDI for patients with WHIM syndrome in the European Union. Executive Chairman Adam Craig noted that the approval reinforces the broader commercial and therapeutic potential of the company’s rare disease platform and will support future commercialization efforts through European partner Norgine.
Earlier, on April 29, X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) announced that the European Commission had formally approved Xolremdi capsules for the treatment of patients with WHIM syndrome across the European Union. Management described the approval as an important milestone that expands access to the therapy beyond the United States while validating the company’s targeted approach to treating rare hematologic disorders. In addition to ongoing commercialization efforts, the company continues advancing its global Phase 3 trial program evaluating mavorixafor in chronic neutropenia.